UCB

UCB is a global biopharmaceutical company headquartered in Brussels. In 2006 it had global reveues of 2.5 billion euro, emplyed approximately 8,400 people and operated in 40 countries.

On its website it states that its primary focus is on products in "the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology."

Funding 'Patient Groups'
In 2006, ECB contributed CHF 30,000 to the European Patients' Forum, a group overwhelmingly funded by the drug industry. One of its priority activities has been to support proposals to overturn the European Union ban on direct-to-consumer advertising. (See Direct-to-consumer advertising: The Campaign To Overturn Europe's Ban for the details of the history of the debate in Europe).

Other SourceWatch Resources

 * Drug industry
 * Direct-to-consumer advertising
 * Direct-to-consumer advertising: The Campaign To Overturn Europe's Ban

Contact Details
UCB S.A. Alle de la Recherche, 60 1070 Brussels Belgium Tel: +32/2/559.99.99 Fax: +32/2/559.99.00 Website: http://www.ucb-group.com/